Sanofi China’s innovative drug in the cardiovascular field, Dolivit, Clopidogrel and Aspirin Tablets (hereinafter referred to as “Doliwei”) was recently prescribed by Huo Yong, director of the Department of Cardiovascular Medicine, Peking University First Hospital, in Beijing. , marking the official usher in a new treatment option for patients with cardiovascular disease in my country. On May 22, Dolivi was launched in China for the prevention of atherothrombotic events in adult patients with acute coronary syndrome.
Acute coronary syndrome is a group of clinical syndromes caused by acute myocardial ischemia, mainly due to the rupture or erosion of unstable plaques in the coronary arteries Complete or incomplete occlusive thrombus formation. These include ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, and unstable angina pectoris, the former two being collectively referred to as acute myocardial infarction. Among them, the average hospitalization cost of patients with ST-segment elevation myocardial infarction was 40,500 yuan, and the in-hospital mortality rate also rose from 3.29% in 2019 to 3.48%, bringing a heavy burden to China’s cardiovascular disease.
Huo Yong told reporters that antiplatelet therapy is very important for all atherosclerosis to prevent thrombosis events, or to treat thrombosis events.
“Atherosclerotic disease accounts for more than half of all human deaths from diseases. The pathogenesis of atherosclerotic disease should be said to be ‘there is no event without thrombosis’.” Huo Yong said that the patient There is atherosclerotic disease, there are vascular lesions, there are plaques, there are stenoses, and even if there are symptoms, it will not be fatal. But all deaths of patients are caused by thrombosis, almost without exception, which is a definite conclusion after a century of knowledge.
Huo Yong said that in clinical treatment, dual antiplatelet therapy based on aspirin combined with clopidogrel is the antithrombotic basis for patients with acute coronary syndrome, but there are still low compliance. Current status of treatment. According to research statistics, among 15,000 adult hospitalized patients with acute coronary syndrome, only 19.4% continued dual antiplatelet therapy to 12 months. On the other hand, the East Asian patient population with acute coronary syndrome has a higher risk of bleeding than the Western patient population, with gastrointestinal bleeding being the most common type of bleeding. Therefore, there is an urgent need for more practical and effective means to help solve the dilemma of antiplatelet therapy.
It is reported that the clopidogrel-aspirin tablets listed this time are single-tablet compound preparations, which will release aspirin in the intestinal tract through the innovative technology “Tab in tab” (tablet-in-a-tablet). It dissolves in the stomach and has a rapid onset of action, thereby reducing gastrointestinal adverse reactions caused by aspirin. At the same time, the daily administration of one tablet not only reduces the patient’s medication burden, but also improves the patient’s medication compliance and further improves the patient’s clinical prognosis.
Image source: provided by respondents